Summary of Sight Sciences, Inc. (SGHT) Q1 2026 Earnings Call

1Key Financial Results and Metrics

Total Revenue: $19.7 million, a 13% increase year-over-year.

Interventional Glaucoma Revenue: $18.3 million, up 7% from the prior year.

Interventional Dry Eye Revenue: $1.4 million, nearly doubling from $0.4 million in Q1 2025.

Gross Margin: 86%, consistent with the prior year; Interventional Glaucoma at 87% and Interventional Dry Eye at 72%.

Operating Expenses: $29.4 million, a 2% increase, primarily due to a one-time $5.4 million fee related to a patent case. Adjusted operating expenses were $21.2 million, down 14%.

Net Loss: $13 million, or $0.24 per share, compared to a loss of $14.2 million, or $0.28 per share in Q1 2025.

Cash Position: $85 million at quarter-end, down from $92 million at the end of 2025.

2Strategic Updates and Business Highlights

Interventional Glaucoma: Continued growth with a focus on expanding the combo cataract market and activating stand-alone interventions. The introduction of OMNI Edge has been positively received.

Interventional Dry Eye: Strong adoption of TearCare technology, with significant growth in customer accounts and utilization rates. The company is expanding its commercial team to enhance execution.

Market Dynamics: There is a recognized overlap between glaucoma and dry eye patients, which the company aims to leverage for cross-selling opportunities.

Patent Case: A favorable ruling in the patent infringement case against Alcon, with potential ongoing royalties of 10% on Hydrus revenue, though cash has not yet been received.

3Forward Guidance and Outlook

Revenue Guidance for 2026: Raised to $83 million to $89 million, reflecting a growth of 7% to 15% compared to 2025.

Interventional Glaucoma: $77 million to $81 million (growth of 2% to 7%).

Interventional Dry Eye: $6 million to $8 million (compared to $1.6 million in the prior year).

Q2 Expectations: Anticipated low double-digit revenue growth overall, with Interventional Dry Eye projected to generate $1.5 million to $2 million.

4Bad News, Challenges, or Points of Concern

Cash Usage: Although cash burn decreased, the company still reported a net loss and a decline in cash reserves.

Competitive Pressures: The market for glaucoma treatments is competitive, and the company must continue to innovate to maintain its leadership position.

Regulatory Risks: The timing of FDA clearance for OMNI Ultra is uncertain, which could impact revenue if delayed.

Market Access: While there is progress in reimbursement discussions, the timing and success of expanding payer access remain uncertain.

5Notable Q&A Insights

Utilization Trends: Management indicated that many accounts are still early in their usage of TearCare, suggesting significant growth potential as practices optimize workflows.

Sales Team Expansion: The Interventional Dry Eye team is small but growing, with a focus on regions with established Medicare fee schedules.

Market Access Strategy: The company is optimistic about securing additional payer wins in 2026, which are critical for scaling the Interventional Dry Eye business.

Synergies: There is a strong recognition among eye care providers of the overlap between glaucoma and dry eye patients, which could enhance cross-selling opportunities. Overall, Sight Sciences demonstrated strong early performance in 2026, with positive growth in both business segments and a strategic focus on leveraging synergies between their product offerings. However, challenges remain in cash management and market access that could impact future growth.